Cancer Lawsuit Information: Other Endocrine Cancer Statistics

Below are statistics relating to Other Endocrine cancer from the National Cancer Institute (NCI). The data indicates trends, rates, and patterns of Other Endocrine cancer in the United States, by sex, and race/ethnicity, survival and stage rates. The National Cancer Institute (NCI) estimates that the incidence of cancer could be reduced by as much as 80-90 percent if environmental causes such as diet, tobacco, and alcohol, as well as radiation, infectious agents, and substances in the air, water, and soil were addressed.

If you are suffering from a cancer caused by an industrial pollutant, or you were misdiagnosed by a doctor or oncologist, you may be able to file a lawsuit and get compensation for your pain and suffering, make sure your family is provided for, and help make sure that no one else in your community is exposed to dangerous carcinogens. To get your free case evaluation, fill out this simple form. Your case will be evaluated within 24 hours. If you want to help a friend who needs a cancer attorney, please click here.

The American Cancer Society estimates that 1,960 men and women (1,050 men and 910 women) will be diagnosed with and 880 men and women will die of cancer of the other endocrine in 2005.

The following information is based on NCI and other statistics from NCI’s analysis of SEER incidence data and NCHS mortality data.

Incidence & Mortality

From 1998-2002, the median age at diagnosis for cancer of the other endocrine was 48 years of age. Approximately 24.9% were diagnosed under age 20; 9.6% between 20 and 34; 9.3% between 35 and 44; 16.3% between 45 and 54; 15.2% between 55 and 64; 13.3% between 65 and 74; 9.1% between 75 and 84; and 2.4% 85+ years of age.

The age-adjusted incidence rate was 0.7 per 100,000 men and women per year. These rates are based on cases diagnosed in 1998-2002 from 13 SEER geographic areas. Incidence rates by race and sex were:

US Mortality

From 1998-2002, the median age at death for cancer of the other endocrine was 56 years of age. Approximately 20.3% died under age 20; 5.4% between 20 and 34; 8.3% between 35 and 44; 13.2% between 45 and 54; 14.1% between 55 and 64; 18.8% between 65 and 74; 15.1% between 75 and 84; and 4.8% 85+ years of age.

The age-adjusted death rate was 0.3 per 100,000 men and women per year. These rates are based on patients who died in 1998-2002 in the US. Death rates by race and sex were:

Trends in Rates

Trends in rates can be described in many ways. Information for trends over a fixed period of time, for example 1992-2002, can be evaluated by the annual percentage change (APC). If there is a negative sign before the number, the trend is a decrease; otherwise it is an increase. If there is an asterisk after the APC then the trend was significant, that is, one believes that it is beyond chance, i.e. 95% sure, that the increase or decrease is real over the period 1992-2002. If the trend is not significant, the trend is usually reported as stable or level. Joinpoint analyses can be used over a long period of time to evaluate when changes in the trend have occurred along with the APC which shows how much the trend has changed between each of the joinpoints.

The joinpoint trend in SEER cancer incidence with associated APC(%) for cancer of the other endocrine between 1975-2002 was:

The joinpoint trend in US cancer mortality with associated APC(%) for cancer of the other endocrine between 1975-2002 was:

Survival & Stage

Survival rates can be calculated by different methods for different purposes. The survival rates presented here are based on the relative survival rate, which measures the survival of the cancer patients in comparison to the general population to estimate the effect of cancer. The overall 5-year relative survival rate for 1995-2001 from 9 SEER geographic areas was 60.3%. Five-year relative survival rates by race and sex were: 59.3% for white men; 59.1% for white women; 68.3% for black men; 49.0% for black women.

The stage distribution based on historic stage shows that 30% of other endocrine cancer cases are diagnosed while the cancer is still confined to the primary site (localized stage); 32% are diagnosed after the cancer has spread to regional lymphnodes or directly beyond the primary site; 32% are diagnosed after the cancer has already metastasized (distant stage) and for the remaining 7% the staging information was unknown. The corresponding 5-year relative survival rates were: 76.8% for localized; 72.5% for regional; 33.1% for distant; and 56.4% for unstaged.

Source: National Cancer Institute www.cancer.gov

Click To Talk To Us Online

see also:

Oral OralCancer Lawsuit Toxic Tort Lawyers/Attorneys
OralToxic Tort Lawsuit Lawyer/Attorney

Melanoma Melanoma Cancer Lawsuit Toxic Tort Lawyers/Attorneys
Melanoma Toxic Tort Lawsuit Lawyer/Attorney

Cancers K - O Environmental Cancer Lawsuit: Cancers cause by Pollutants--Free Eval.
Get A Free Review of Your Cancer Lawsuit from an Environmental Lawyer